Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

Palantir — The stock jumped 11% following the AI-powered software provider's fourth-quarter earnings beat . Palantir reported ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...